Get started

Stockstobuy

NBIS Nebius Group Among My Top 10 Picks for 2025 | Price TargetNebius Group N.V. (NBIS) presents a compelling bullish case for a potential doubling of its stock price by the end of 2025, driven by several fundamental factors that highlight its growth trajectory within the rapidly expanding AI infrastructure market. NVIDIA Corporation (NVDA) has made a significant investment in Nebius Group N.V. (NBIS), contributing to a $700 million funding round aimed at expanding Nebius's AI infrastructure capabilities. This investment aligns with NVIDIA's strategic focus on enhancing its presence in the rapidly growing AI market. Explosive Revenue Growth: Nebius Group has demonstrated remarkable revenue growth, with Q3 2024 revenues reaching $43.3 million, representing a 1.7-fold increase compared to the previous quarter and a staggering 766% year-over-year increase. This surge is primarily driven by the company's core AI infrastructure business, which grew 2.7 times quarter-over-quarter and 6.5 times year-over-year. Analysts expect this momentum to continue, projecting annual revenues of approximately $731.96 million for 2025, reflecting a robust demand for AI-centric services and solutions. Strategic Investments in AI Infrastructure: The company is heavily investing in expanding its GPU cluster capabilities and data center capacity, with plans to allocate over $1 billion towards these initiatives. This strategic focus on enhancing AI infrastructure positions Nebius to capture significant market share as the global demand for AI technologies continues to rise. The annualized run-rate for its cloud revenue has already surpassed $120 million, indicating strong customer adoption and a growing client base that includes Fortune 500 companies. Strong Market Position and Competitive Advantage: Nebius Group is uniquely positioned within the AI infrastructure landscape, specializing in full-stack solutions that cater to developers and enterprises looking to leverage AI technologies. As businesses increasingly prioritize AI integration into their operations, Nebius's comprehensive offerings make it an attractive partner for organizations seeking to enhance their technological capabilities. The company’s ability to provide scalable solutions will be crucial as the demand for AI services expands. Healthy Financials and Cash Reserves: As of September 30, 2024, Nebius reported cash and cash equivalents totaling approximately $2.29 billion, providing a solid financial foundation to support its growth initiatives without excessive reliance on debt. This strong liquidity position allows Nebius to invest aggressively in technology and infrastructure while maintaining operational flexibility 14. Additionally, with gross margins projected to remain robust at around 55% in 2025, the company is well-positioned to improve profitability as revenues grow.
NASDAQ:NBISLong
by TopgOptions
2
Netflix on the Rise Bullish Breakout in Motion!Trendline Support The price is respecting an ascending trendline, indicating a strong bullish sentiment. Recent candles have bounced off this support line, confirming its reliability. Breakout Confirmation The price has broken above a key horizontal resistance level around $870. This breakout suggests bullish continuation, especially with volume support. Risk-to-Reward Setup A well-defined risk-to-reward ratio is visible. Stop-loss appears to be placed below $853, protecting against a false breakout. Target set around $939 aligns with a significant resistance zone, offering a potential reward. Indicators Positive price momentum is evident, with higher highs and higher lows forming. Likely supported by broader market strength in tech stocks. Next Steps Monitor the price action for sustained movement above $870. A retracement to retest the breakout level could provide a secondary entry. Key resistance to watch: $900 and $939. NFLX is poised for a bullish continuation, with the current setup offering a high-probability trade opportunity.
NASDAQ:NFLXLong
by wolfchemist
1
Berkshire Hathaway | No More Apple Pie & Bank Bread!No More Apple Pie and Bank Bread | Buffett’s Recipe for Market Caution Berkshire Hathaway has recently disclosed its earnings amid fluctuating around a $1 trillion valuation. A notable update is its continued reduction of stakes in overvalued assets, including a 20% decrease in holdings of Apple and Bank of America, boosting its cash reserves to $325 billion Although Warren Buffett himself isn't favoring share buybacks at present, Berkshire Hathaway stands as a compelling investment option Why Berkshire Hathaway's $325 Billion Cash Pile Signals Market Caution The company's net earnings remain subject to significant fluctuations due to rules requiring valuation changes of investment holdings. However, there was a slight decline in operating earnings, mainly driven by lower insurance underwriting income. Despite this, that segment is historically volatile, and year over year aka YoY, the company has maintained strong performance. Yea2date aka YTD, operating earnings have risen over 10%, totaling just under $33 billion compared to just below $29 billion last year. This points to an annualized earnings estimate of approximately $44 billion, implying a price2earnings aka P/E ratio of about 22, without factoring in over $320 billion in cash and significant investment holdings. Excluding cash and investments, the adjusted P/E ratio is closer to single digits. Share buybacks have paused, reflected in a ~1% decrease in the outstanding shares YoY, signaling Berkshire's assessment of current market valuations. Segment Highlights The various business units within Berkshire Hathaway showcase its robust asset base and earning capacity. Insurance underwriting income saw a sharp YoY drop, but other business areas performed strongly. Income from insurance investments remained solid, and BNSF, its railroad subsidiary, also showed strong results despite a double digit YoY decline. Berkshire Hathaway Energy continues its growth, cementing its position in the utility sector with significant renewable energy ventures. For context, NextEra Energy (NEE), with a market capitalization of $160 billion, posted quarterly earnings around 10% higher. Berkshire's other controlled and non-controlled businesses contribute over $13 billion annually, underpinning its diversification and consistent earnings performance. This strength across segments underscores its formidable financial health. Market Context Currently, market valuations are elevated by historical standards. Excluding periods of earnings dips, market enthusiasm is exceptionally high, with the S&P 500 P/E ratio nearing 30x, approaching levels last seen in 1999. Buffett and Berkshire appear to view a 3% yield from such a P/E as unattractive, especially when bonds offer higher returns. The 2008 Playbook Berkshire's track record of effectively utilizing its cash reserves is notable. Excluding its insurance float, the company still holds $150 billion in cash. During the 2008 financial crisis, Berkshire leveraged its liquidity for strategic investments in companies like General Electric, Swiss Re, Dow Chemical, and Bank of America, as well as finalizing the full acquisition of BNSF in 2010. This proactive use of capital proved advantageous. The current strategic sale of assets suggests Berkshire is preparing for potential market downturns. Given high S&P 500 valuations, reallocating part of an S&P 500 position into Berkshire Hathaway could be wise, ensuring exposure to a cash-rich portfolio capable of seizing future opportunities. Meanwhile, Berkshire’s earnings are valued lower than the broader market, potentially minimizing major downturn risks. Investment Risks A key risk is that timing the market is inherently challenging, with the adage "time in the market beats timing the market" serving as a caution. If Berkshire's market outlook is incorrect, its $300+ billion in cash could underperform while broader markets remain strong, which would diminish its appeal as an investment. Final Thoughts Berkshire Hathaway has taken the bold step of liquidating some of its most significant and priciest holdings, opting to incur capital gains taxes to increase liquidity. This move has bolstered its cash position to $325 billion, $150 billion above its float level. Meanwhile, its strong operational businesses continue generating healthy cash flow. Drawing on its successful strategies during the 2008 crisis, Berkshire appears to be positioning itself for another downturn amid current high market valuations. We advise investors to consider shifting part of their S&P 500 exposure into Berkshire Hathaway for enhanced diversification and potential benefits in a market correction, long story short Berkshire Hathaway remains a robust investment opportunity but wont make millionaire! What do you think moonypto fam?
NYSE:BRK.A
by moonypto
From Market Underdog to Tech Titan| AppLovin’s Explosive Growth AppLovin: Making Ads Great Again, One Algorithm at a Time AppLovin Corp, a prominent software company valued at $57 billion, offers an advanced mobile marketing platform. Over the past year, its stock price has surged by an impressive 500%, far outpacing the S&P 500’s 39% increase. The company’s financial growth is equally remarkable, with a year over year revenue boost of 40%, a 188% jump in operating profits, and a 300% surge in net income in its latest quarterly report With 40% of the company held by insiders and a shareholder friendly stance that includes share buybacks, AppLovin presents a compelling investment opportunity. Additionally, its valuation remains competitive relative to other software companies, supporting my "buy" rating. From Ad Nerds to Tech Lords, AppLovin’s Secret to Winning Over Wall Street AppLovin operates a comprehensive software platform that helps clients achieve crucial KPIs, such as revenue growth and business expansion. Leveraging AI, its software platform stands out as a powerful tool for advertisers, providing capabilities like automated marketing, customer engagement, and monetization. It’s built to optimize targeted content delivery to the most suitable audience, supported by analytics and monetization features that drive maximum value. At the core of AppLovin’s technology is AXON, an AI engine that powers AppDiscovery. This feature matches advertiser demand with publishing opportunities through a sophisticated real-time auction algorithm, shifting from traditional waterfall systems to an intelligent, programmatic approach. AppLovin has positioned itself as a leader in the future of advertising, driven by its cutting-edge AI capabilities. I believe there’s immense growth potential here that the company is just beginning to explore. Performance In the third quarter, AppLovin reported a 39% year-over-year revenue increase, moving from $864 million to $1.2 billion. This marks its highest-ever quarterly revenue and extends its streak of sequential topline gains to seven quarters. For the first nine months of 2024, AppLovin saw a 43% year-to-date revenue increase, largely fueled by a 76% rise in software platform revenue. This growth was driven by AppDiscovery, whose installations surged by 39% in Q3, underscoring its strong appeal to advertisers. Beyond software platform growth, AppLovin’s in-app purchases and advertising revenues also increased modestly by 3% and 7%, respectively, despite challenging comparisons, supported by a 53% boost in advertising impressions. The company achieved record operating cash flows of over $550 million in Q3, alongside significant margin improvements across gross, operating, and EBITDA levels. These gains highlight the company’s explosive growth and underscore the stock’s 500% rise over the past year. Given AppLovin’s strategic success and positive advertiser response, I anticipate ongoing improvements in cash flow and profit margins. With over $3.3 billion spent on share buybacks since 2022—$980 million in 2024 alone—the company continues to reward its shareholders while capitalizing on its profitable AI-driven platform. Valuation Although APP’s trailing P/E ratio of 74.52 and PS ratio of 19.33 might appear high compared to the IT sector averages, a comparison with peers in the Application Software industry reveals a different perspective. In a peer group of large software companies, APP ranks third in EV/Sales ratio at 18.65 but also boasts a forward topline growth rate of over 24.1%, placing it among the top performers. This high growth potential appears to justify the stock’s premium, positioning it attractively in terms of PS ratio relative to anticipated growth. Despite recent heavy buying, APP remains an appealing value investment. As long as it maintains its relative positioning, I continue to view the stock favorably. Risks Despite my optimism, I recognize that AppLovin’s momentum could be part of a broader AI-driven market surge, raising concerns about a potential AI bubble. If the market faces a downturn similar to the dot-com bubble, APP could experience a sharper decline than its peers, especially given its relatively weak balance sheet. Additionally, with an RSI of 96 signaling heavy overbuying, there may be potential for a future correction. While APP’s 500% rise is impressive, it could be vulnerable if the market undergoes a broader correction Conclusion Advertising is on the cusp of an AI driven transformation, and AppLovin is well-positioned to capitalize on this shift with its powerful AI-enabled platform. Despite the stock’s impressive 12-month performance, there’s still significant growth potential
NASDAQ:APPLong
by moonypto
2
Is Apple Stock Really Worth Investing in January 2025?Strong weekly demand level took control. Expecting a decent reaction. As we enter 2025, the financial landscape is buzzing with excitement and uncertainty. Investors are searching for promising opportunities, and one name that consistently tops the charts is Apple Inc. (NASDAQ: AAPL). Love it or hate it, this tech giant has become synonymous with innovation and growth—drawing both seasoned investors and newcomers alike to its stock like moths to a flame.
NASDAQ:AAPLLong
by AlfonsoMoreno
Quantum Corporation: Major Levels to WatchGood morning, trading family! Quantum Corporation is at a crucial point: Above $34.50: A breakout could push us to $50 or even higher. Below $29: The downside opens up to the $6–$12 range. Stay sharp as these levels could define the next big move. This Sunday, I’m hosting a Master Your Mind Traders Class to help you build a stronger trading mindset and strategy. Seats are limited—send me a DM for details! Kris/Mindbloome Exchange Trade What You See
NASDAQ:QMCO
by Mindbloome-Trading
Micron Technology: Bearish or Ready to Break Out?Good morning, trading family! Micron (MU) is at an important spot right now: If we move lower, I’m watching $97 and $96 as key levels, with potential for more downside. If we hold above $100, there’s room to climb to $102, $103, and $104. A break above $104 could mean a smoother ride higher. I’m also hosting a Master Your Mind Traders Class this Sunday to help you refine your skills and mindset. Want to join? Send me a message for details. Kris/ Mindbloome Exchange Trade What You See
NASDAQ:MU
by Mindbloome-Trading
2
Mangalam Cement: Profitable Long TradeTrade Overview: Mangalam Cement demonstrated a strong bullish move on the 15-minute chart, with all targets (TP1 to TP4) successfully achieved using the Risological Swing Trading Indicator . The trade capitalized on a well-timed entry near ₹919.05, with a stop loss (SL) set at ₹907.45, and hit the final target of ₹994.05, showcasing high accuracy. Key Levels: Entry Price: ₹919.05 Stop Loss: ₹907.45 Take Profits: TP1: ₹933.35 TP2: ₹956.55 TP3: ₹979.75 TP4: ₹994.05 Fundamental Analysis: Recent news supports the price movement: Strong Quarterly Earnings: Mangalam Cement reported a net profit of ₹32.8 million for the September quarter, signaling financial resilience. Improved Profitability: The company has shown consistent growth in quarterly profits, boosting investor confidence. Market Stats: Current Price: ₹1,007.75 (+1.66%) Volume: 142.78K (above average) 52-Week Range: ₹610.30 - ₹1,093.70 Mangalam Cement's robust fundamentals and the Risological Indicator's precision have once again delivered a profitable trade setup.
NSE:MANGLMCEMLong
by ProfitsNinja
JSW ENERGY BREAKOUT LEVELS JSW Energy - Potential Breakout Setup 📈 Analysis: JSW Energy is showing signs of building momentum. The stock is currently testing a key resistance zone at ₹ . If the price breaks above this level, we could see a strong breakout rally. A clean breakout above ₹ would confirm the bullish trend, potentially targeting ₹ in the near term. 🔑 Key Factors to Monitor: Look for an increase in volume as confirmation of the breakout. A close above ₹ on high volume will likely push the stock higher. The RSI is showing strong bullish momentum, suggesting more upside potential. Watch out for any reversal patterns or resistance re-tests after the breakout. 💡 Trade Idea: 📅 Timeframe: Watch for price action over the next few sessions to confirm the breakout. 📌 Disclaimer: This post is for educational purposes and does not constitute financial advice. Always perform your own analysis or consult a professional before making any trades.
NSE:JSWENERGYLong
by jagur_dfo
Suntek realtyFrom the Covid low of 145 zone prices have given a rally for two years and made a high of 590 in Jan'22. From there prices have retraced 50% and made a low of 272 and recovered back to hit new all time high. Prices have made a continuation Head & shoulders pattern whose neckline is 500 zone. Prices have given the breakout the neckline and currently retesting the same. The measured target of the pattern is 950 zone. Prices are likely to continue the uptrend towards 950-1000 zone in the coming months. The key level for the same is 380.
NSE:SUNTECKLong
by TradingSutra
Linde plc | LIN Linde, Timeless Excellence Linde is a timeless business with even better stability than other basic materials businesses. The company works in gases and has a near-unbroken EPS growth record of 8% annually Linde is a market leader, and if you invest in the company, you're investing in the world's largest company for industrial gases. The company was originally a result of a takeover of British BOC in 2006, and again the 2018 merger of Linde and Praxair, a US company. On the macro upside, there was a 1) supportive regulatory framework in the USA and in the EU on green opportunities and hydrogen, 2) the Ukraine invasion was also a key catalyst towards the energy transition, 3) the EU chip acts with €43 billion in supporting funds as well as the United States Chips and Science Act development for a value of approximately $52 billion, and 4) higher needs of specialty gas in EV car. Related to the micro upside, the company is more diversified on a GEO revenue basis and sells different product solutions starting from cylinders to bulk liquid. In addition with a follow-up note titled "Positive News Ahead", we reported Linde's lower cost structure with the Frankfort delisting. Aside from removing the dual listing expenses, we positively view this development because US companies' P/E multiple are usually higher compared to the EU one. To support our MACRO buy case recap, in the second quarter, Linde announced two new projects with Evonik and Heidelberg Materials (both companies covered by our internal team). The company signed a long-term agreement to produce green hydrogen for Evonik in a 9-megawatt alkaline electrolyzer plant in Singapore. With Heidelberg, Linde will build a large-scale carbon capture close to the Lengfurt plant in Germany. As a reminder, cement production is estimated to be responsible for around 7% of global in 2022, APD's earnings per share were at $8.38, and Linde's earnings per share were fairly similar at $8.23. For 2023, Air Products and Chemical EPS guide a midpoint at $11.40 while Linde's EPS is forecasted at $13.65. Looking at the ROCE, in Q4 2022, APD stood at 11.7% and Linde at 13.4%. In the last quarter, APD’s ROCE was flat on the two-year comparison, while Linde’s after-tax ROCE reached 24.0%. While there are some business & regional nuances between the two leading companies (for instance, APD is lacking U.S. packaged gas business), here at the Lab, we believe are more inclined toward Linde, particularly when organic growth has been fairly similar. Cross-checking APD and Linde's last quarter results, we should recall that on a comparable basis, the German player volumes were flat with an average selling price up by 8%. On the other hand, APD increased its volume by 6% with an increase in the average selling price of 8% too. APD adj EBITDA grew by 13% while Linde achieved a plus 11%. However, Linde's EU exposure is greater than APD. Therefore, this is supportive of Linde's bottom line. In numbers, excluding the Engineering divisional performance, Linde's EMEA sales reached $2,177 million and represented 29.72% of the company's total sales. Compared to Q1 2022 number, turnover grew by 10% and was driven by a 13% of cost pass-through increase.
LLong
by moonypto
6
TEVA Pharmaceutical is a BUY?As the excitement around AI continues to wane, concerns about a potential US recession grow, and the risks of a major conflict in the Middle East linger, Teva Pharmaceutical's stock is entering an accumulation phase above $18, signaling strong bullish sentiment. Why Wall Street's bullish in this drug company ? First, on July 31, Teva announced its financial results for the second quarter of 2024, demonstrating that the company remains resilient despite years of investor disappointment following the Allergan Generics acquisition and the loss of Copaxone exclusivity. However, over the past 18 months, under Richard Francis' leadership, the company has shown significant growth, with increasing revenue and profits in its European and US segments, the successful launch of biosimilars and Uzedy, and record sales of Austedo, its blockbuster treatment for certain neurological disorders. Alongside rising sales of generics, Teva has also accelerated the development of innovative medications, which could set new standards in treating schizophrenia and some chronic inflammatory diseases. For instance, on July 25, the company delighted investors by announcing that it had completed patient enrollment ahead of schedule in a Phase 2b clinical trial assessing the efficacy and safety of duvakitug for treating ulcerative colitis and Crohn's disease, driven by strong interest from healthcare professionals and patients. Teva Pharmaceutical's financial performance and 2024 outlook After years of challenges, the Teva revenue exceeded $4 billion once again, reaching $4.14 billion in the second quarter of 2024, a 7.4% year-on-year increase that surpassed consensus estimates by $114 million. Meanwhile, another critical financial metric, earnings per share aka EPS, exceeded my expectations despite rising costs associated with conducting expensive clinical trials for assessing the efficacy of Teva's biosimilars and experimental drugs targeting neurodegenerative and autoimmune disorders. The Israeli company's EPS reached $0.61 for the three months ending June 30, 2024, marking a 27.1% increase from the previous quarter and surpassing analysts' forecasts by six cents. What factors contribute to Teva Pharmaceutical's success? To answer this objectively, it's essential to examine not only the impact of sales from individual medications but also to delve deeper into how effectively the company's management is handling the development of each of Teva's business segments. We'll begin with the United States segment, which significantly influences Teva's financial standing. For the three months ending June 30, 2024, revenue in this segment reached $2.12 billion, reflecting an 11.5% year on year increase and a 22.3% rise from the previous quarter. First, Teva's revenue and profit growth were largely fueled by significant advancements in its generics business, despite facing stiff competition from companies like Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Perrigo (PRGO), and others in the market. In the second quarter, total sales of generic products reached approximately $1.03 billion, marking a 26.6% increase from the previous quarter. What factors led to the recovery of Teva's generics business? The resurgence of Teva's generics business in the U.S. was primarily driven by the launch of an interchangeable biosimilar to AbbVie's Humira (ABBV), rising demand for generic versions of Bristol-Myers Squibb's Revlimid (BMY), a major blockbuster for treating multiple myeloma, the generic version of Novo Nordisk's Victoza (NVO) for type 2 diabetes, and the expansion of its drug portfolio. The soaring sales of Copaxone and the strong performance of Austedo, which I analyzed in detail in a previous article, were also notable. Despite increasing competition in the U.S. tardive dyskinesia therapeutics market from Neurocrine Biosciences' (NBIX) Ingrezza, Austedo's demand continued to grow. Sales of the Austedo franchise reached $407 million in the second quarter of 2024, a 32.1% YOY increase, driven by expanded patient access and the FDA's late May approval of Austedo XR in four new tablet strengths, giving doctors more options for optimizing treatment regimens for adults with tardive dyskinesia and Huntington's disease-associated chorea. I also want to highlight Uzedy, a long-acting formulation of risperidone, as another key contributor to Teva's revenue growth. Although the company launched Uzedy in May 2023 and has not yet disclosed its sales figures, it has been approved for the treatment of schizophrenia. However, as evident from the chart below, the total number of prescriptions has been steadily increasing month over month. Teva Pharmaceutical estimates that its revenue from Uzedy will be around $80 million in 2024, exceeding my expectations by approximately $25 million. Despite ongoing growth in demand for this anti-CGRP migraine medication, its sales amounted to $42 million in the second quarter of 2024, a decrease of 6.7% compared to the previous quarter and 19.2% year-on-year. This decline was primarily due to an increase in sales allowances linked to a one-time event. Now, let's turn our attention to the company's Europe segment, which generates most of its revenue through sales of generics and biosimilars. For the three months ending June 30, 2024, sales in this segment reached approximately $1.21 billion, reflecting a 4.3% year-on-year increase, driven by new product launches and growing demand for Ajovy. However, sales of respiratory medications continue to face challenges due to a decline in cold and flu cases. As anticipated, demand for Copaxone is weakening, not only because of competition from generic versions but also due to the availability of more effective treatments for relapsing forms of multiple sclerosis, such as Bristol-Myers Squibb's Zeposia, Roche Holding's Ocrevus and TG Therapeutics' Briumvi (TGTX). Lastly, let's discuss the International Markets segment, which focuses on commercializing Teva's drugs across 35 countries, including Canada and Japan. In the second quarter, revenue for this segment was $593 million, representing a 2.6% YOY increase. However, the segment's profit dropped significantly to $73 million quarter over quarter, due to declining demand for Copaxone, increased R&D expenses, and higher sales and marketing costs related to the distribution of Austedo in China. The question arises: "Are there any positives?" The short answer is yes. Teva's revenue from generic drugs has been on an upward trend in recent years, with the exception of the fourth quarter of 2023. For the three months ending June 30, 2024, it reached $488 million, marking a 2% increase from the previous quarter. What is driving this sales growth? Despite challenges such as the weakening of foreign currencies like the Japanese yen, ruble, and Chinese yuan against the US dollar, increased competition in Japan, and ongoing inflationary pressures on the pharmaceutical industry, Teva’s management has successfully navigated these obstacles by expanding its medication portfolio and raising prices. Now lets talk about Risks Several risks could negatively impact Teva Pharmaceutical’s investment appeal in the medium to long term. At the end of July, Teva reported financial results for the second quarter of 2024, which not only exceeded analysts' expectations but also reinforced confidence in the effectiveness of the business strategies implemented by CEO Richard Francis. In addition to accelerating the recovery of the company's generics business, boosting sales of Austedo and Uzedy, and launching the Humira biosimilar in May, Teva also raised its full-year 2024 guidance. With a P/E ratio of 6.35x, which suggests the stock is trading at a discount compared to the broader healthcare sector, other positives include the reduction of Teva’s net debt by about $2 billion over the past 12 months, as well as year-over-year growth in gross and operating profits. To understand who truly holds control over Teva Pharmaceutical Industries Limited, it's crucial to examine the company's ownership structure. The largest share of ownership, approximately 69%, is held by institutional investors. This means that this group stands to experience the greatest potential for gains or losses, depending on the company's performance. The company has also accelerated the development of its product candidates under its "Pivot to Growth" program, which aims to strengthen its balance sheet and enhance its investment appeal by expanding its biosimilar portfolio and bringing potential best-in-class drugs for cancer, neurological, and autoimmune disorders to market. So TEVA Pharmaceutical is a BUY? YUP
NYSE:TEVALong
by moonypto
DJT: Will It Break $33.85 or $38.55 First? DJT is at a tipping point, and it could go either way. Here’s what to watch so you’re ready for the next big move. 1) If DJT Drops Below $33.85 If this level breaks, things could get rough. Here’s what might happen: -$28–$26: This is the first stop where the price might chill for a bit. -$10: If the selling gets heavy, this is where we could end up. 2) If DJT Pops Above $38.55 If the bulls take charge, it could be time to ride the wave higher: A break above $38.55 could spark a nice rally and push the price upward. What’s the Plan? -Keep an eye on $33.85 and $38.55—they’re the magic numbers. -Be patient and wait for a clear move before jumping in. If this makes sense, toss me a like or follow. Got questions about DJT or another stock you’re stuck on? Hit me up in the DMs—I’m here to help. And hey, if you’re feeling burned out or stressed about trading, let’s talk. I’m all about helping you find your balance and keeping things sustainable. Chill, stay focused, and let’s catch the next wave together! Kris/ Mindbloome Exchange Trade What You See
NASDAQ:DJT
by Mindbloome-Trading
2
QMCO at a Make-or-Break Moment: 5 Key Levels to Watch Now Morning Trading Family QMCO is approaching a critical crossroads, and the next move could bring some serious action. Let’s break it down with key levels and what they mean for traders. If we break below $65.46 The outlook turns bearish. These are the levels to watch on the way down: $60: First stop. This is where buyers might step in to test the waters. $55: A deeper pullback that could bring more attention from the market. $52: A critical level. If we hit this, it’s time to reevaluate what’s next. If we break above $68.37 This would signal a potential shift in behavior, and the bulls might take over. Here’s what could happen: $70: The next challenge for price to clear. $73: A key level that could act as resistance. Above $73? That’s the green light for a long position. If the price moves past $73, it’s likely that the trend has flipped, and we could see much higher levels. What You Can Do -Keep a close eye on $65.46 and $68.37. These levels are your signals for the next move. -Plan ahead—set stop-loss levels to manage your risk. -Stick to your strategy and don’t rush into trades without confirmation. If you found this helpful, don’t forget to follow, like, or boost this video. Have questions about other charts or feeling stuck with trading? Send me a DM—I’m here to help! Kris/ Mindbloome Exchange Trade What You See
NASDAQ:QMCO
by Mindbloome-Trading